Who owns ARTIVA BIOTHERAPEUTICS INC?
- Ticker: ARTV
- CUSIP Number: 04317a107
Tip: Access positions for across all investors
Analyze quarterly positions in Artiva Biotherapeutics with up to 7 years of data, all consolidated into one spreadsheet
Download as csv
Download as Excel
Top investors of Artiva Biotherapeutics stock
Who bought or sold ARTIVA BIOTHERAPEUTICS INC this quarter?
| Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
|---|---|---|---|---|---|
| RA Capital Management | 9.9M | $28M | 0% | Sep 2025 |
|
| 5AM Venture Management | 2.4M | $6.8M | 0% | Sep 2025 |
|
| VR Adviser | 1.6M | $4.6M | 0% | Sep 2025 |
|
| venBio Partners | 1.1M | $3.3M | 0% | Sep 2025 |
|
| Citadel Advisors | 798k | $2.3M | 419% | Sep 2025 |
|
| Franklin Resources | 520k | $1.5M | 0% | Sep 2025 |
|
| BlackRock | 294k | $845k | -39% | Sep 2025 |
|
| Millennium Management | 262k | $752k | -20% | Sep 2025 |
|
| Wellington Management Company | 194k | $557k | 0% | Sep 2025 |
|
| Vanguard Group | 159k | $457k | -32% | Sep 2025 |
|
| Bnp Paribas Arbitrage, Snc | 119k | $340k | 14464% | Sep 2025 |
|
| Geode Capital Management | 111k | $319k | -30% | Sep 2025 |
|
| Alyeska Investment Group | 100k | $287k | 0% | Sep 2025 |
|
| Renaissance Technologies | 79k | $227k | 100% | Sep 2025 |
|
| State Street Corporation | 60k | $172k | -5% | Sep 2025 |
|
| Goldman Sachs Group | 50k | $143k | 19% | Sep 2025 |
|
| XTX Topco | 48k | $138k | 100% | Sep 2025 |
|
| Morgan Stanley | 46k | $69k | 100% | Jun 2025 |
|
| Landscape Capital Management | 39k | $112k | 100% | Sep 2025 |
|
| Bridgeway Capital Management | 35k | $101k | 0% | Sep 2025 |
|
| Hrt Financial | 27k | $77k | -65% | Sep 2025 |
|
| Qube Research & Technologies | 26k | $73k | -34% | Sep 2025 |
|
| UBS Group | 21k | $61k | 534% | Sep 2025 |
|
| Two Sigma Investments | 20k | $58k | -5% | Sep 2025 |
|
| Springbok Capital Management | 14k | $41k | 100% | Sep 2025 |
|
| Barclays | 13k | $36k | 566% | Sep 2025 |
|
| Tower Research Capital | 10k | $29k | -1% | Sep 2025 |
|
| Russell Investments | 5.5k | $16k | 0% | Sep 2025 |
|
| FMR | 4.9k | $14k | -88% | Sep 2025 |
|
| China Universal Asset Management | 4.3k | $12k | -13% | Sep 2025 |
|
| Jpmorgan Chase & Co | 4.0k | $12k | -78% | Sep 2025 |
|
| Wells Fargo & Company | 1.7k | $4.9k | -18% | Sep 2025 |
|
| Mirae Asset Global Investments | 944.00 | $2.7k | 0% | Sep 2025 |
|
| Royal Bank of Canada | 840.00 | $2.7k | -25% | Sep 2025 |
|
| Gf Fund Management | 510.00 | $1.5k | -15% | Sep 2025 |
|
| Mark Sheptoff Financial Planning | 400.00 | $1.1k | 0% | Sep 2025 |
|
| EverSource Wealth Advisors | 159.00 | $455.996100 | 100% | Sep 2025 |
|
| Cloud Capital Management | 11.00 | $0 | 100% | Sep 2025 |
|
Who sold out of Artiva Biotherapeutics?
| Fund or Company Name | Date Sold | Shares Held | Valued At |
|---|---|---|---|
| Samsara BioCapital | Jun 2025 | 292k | $440k |
| Woodline Partners | Jun 2025 | 283k | $428k |
| Marshall Wace | Jun 2025 | 52k | $79k |
| Longwood Capital Partners | Jun 2025 | 46k | $69k |
| Jane Street | Jun 2025 | 44k | $66k |
| Squarepoint Ops | Jun 2025 | 41k | $63k |
| Northern Trust | Jun 2025 | 35k | $53k |
| Y-Intercept | Jun 2025 | 32k | $48k |
| Ground Swell Capital | Jun 2025 | 25k | $38k |
| Jain Global | Jun 2025 | 17k | $26k |
| Susquehanna International | Jun 2025 | 16k | $24k |
| Deutsche Bank Aktiengesellschaft | Jun 2025 | 3.4k | $5.1k |
| NISA Investment Advisors | Jun 2025 | 329.00 | $496.987400 |